Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
06.05. | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | 2 | Benzinga.com | ||
TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
02.05. | Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign | 1 | Seeking Alpha | ||
01.05. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M | 3 | Seeking Alpha | ||
01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 335 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
01.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
01.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | An Overview of Tarsus Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
24.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | 1 | GlobeNewswire (USA) | ||
22.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | 1 | GlobeNewswire (USA) | ||
13.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.03. | Tarsus prices $125M stock offering | 4 | Seeking Alpha | ||
13.03. | Tarsus Pharmaceuticals, Inc: Tarsus Announces Pricing of Upsized $125.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
12.03. | Tarsus Pharmaceuticals startet Aktienangebot im Wert von 100 Millionen US-Dollar | 3 | Investing.com Deutsch | ||
12.03. | Tarsus Pharmaceuticals, Inc: Tarsus Announces Proposed $100.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
06.03. | Jefferies raises Tarsus stock target to $58, keeps Buy rating | 6 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,90 | +0,28 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,144 | -0,72 % | Evotec steigt in Mega-Forschungsprojekt ein - Hoffnungsschimmer für Millionen Nierenpatienten | Evotec SE treibt seine Strategie in der personalisierten Medizin weiter voran und verkündet den Beitritt zum renommierten NURTuRE-AKI-Konsortium. Mit diesem Schritt zielt das MDAX- und TecDAX-notierte... ► Artikel lesen | |
CUREVAC | 4,556 | -1,09 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
MODERNA | 23,640 | +1,61 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
STRYKER | 333,30 | -0,09 % | Kurs der Stryker-Aktie verharrt auf Vortags-Niveau (324,7763 €) | Am US-amerikanischen Aktienmarkt ist die Stryker-Aktie aktuell unauffällig. Der jüngste Kurs betrug 374,99 US-Dollar. Die Wertschätzung der Börsenteilnehmer für die Aktie von Stryker hat sich heute... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,335 | -3,05 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
KUROS BIOSCIENCES | 30,880 | +1,51 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen | |
VAXART | 0,441 | -3,67 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 108,55 | +0,23 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ... | Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia
Findings... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 44,970 | +0,18 % | Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous... ► Artikel lesen | |
IMMATICS | 4,722 | -1,05 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
MANNKIND | 3,260 | +1,34 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
RELIEF THERAPEUTICS | 2,270 | 0,00 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
BEONE MEDICINES LTD ADR | 210,00 | -3,67 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert wegweisende Onkologie-Pipeline beim R&D Day | Daten zu BRUKINSA, Sonrotoclax, BTK-CDAC und Kombinationstherapien, die den ungedeckten Bedarf von CLL-Patientengruppen umfassend adressieren Vielversprechende neue Daten aus der Pipeline für... ► Artikel lesen |